Efficacy of etanercept and complete decongestive physical therapy in bilateral lower-limb lymphoedema associated with rheumatoid arthritis: a case report.
Identifieur interne : 003014 ( PubMed/Checkpoint ); précédent : 003013; suivant : 003015Efficacy of etanercept and complete decongestive physical therapy in bilateral lower-limb lymphoedema associated with rheumatoid arthritis: a case report.
Auteurs : Sibel Eyigor [Turquie] ; Hale Karapolat ; Ye Im KirazliSource :
- Advances in therapy [ 0741-238X ] ; 2008.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antirhumatismaux (usage thérapeutique), Association thérapeutique, Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Femelle, Humains, Immunoglobuline G (usage thérapeutique), Lymphoedème (), Lymphoedème (étiologie), Membre inférieur, Polyarthrite rhumatoïde (), Récepteurs aux facteurs de nécrose tumorale (usage thérapeutique), Techniques de physiothérapie, Étanercept.
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- usage thérapeutique : Antirhumatismaux, Immunoglobuline G, Récepteurs aux facteurs de nécrose tumorale.
- étiologie : Lymphoedème.
- Adulte d'âge moyen, Association thérapeutique, Femelle, Humains, Lymphoedème, Membre inférieur, Polyarthrite rhumatoïde, Techniques de physiothérapie, Étanercept.
English descriptors
- KwdEn :
- Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (complications), Combined Modality Therapy, Etanercept, Female, Humans, Immunoglobulin G (therapeutic use), Lower Extremity, Lymphedema (etiology), Lymphedema (therapy), Middle Aged, Physical Therapy Modalities, Receptors, Tumor Necrosis Factor (therapeutic use), Tumor Necrosis Factor-alpha (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antirheumatic Agents, Immunoglobulin G, Receptors, Tumor Necrosis Factor.
- complications : Arthritis, Rheumatoid.
- etiology : Lymphedema.
- therapy : Lymphedema.
- Combined Modality Therapy, Etanercept, Female, Humans, Lower Extremity, Middle Aged, Physical Therapy Modalities.
Abstract
A 54-y-old patient with rheumatoid arthritis (RA) and bilateral lower-limb lymphoedema is presented. Complete decongestive physical therapy (CDP) is the cornerstone of the management programme in all patients suffering from lymphoedema associated with RA, but it is not clear which therapy is the most effective in decreasing the oedema. We report on a patient with bilateral lower-limb lymphoedema associated with RA who, after receiving etanercept and CDP, showed moderate improvement. There is little information on the benefit of etanercept therapy for the extra-articular manifestations of RA. Further research is necessary to confirm the beneficial effect of etanercept and CDP.
DOI: 10.1007/s12325-008-0006-1
PubMed: 18227980
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18227980Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of etanercept and complete decongestive physical therapy in bilateral lower-limb lymphoedema associated with rheumatoid arthritis: a case report.</title>
<author><name sortKey="Eyigor, Sibel" sort="Eyigor, Sibel" uniqKey="Eyigor S" first="Sibel" last="Eyigor">Sibel Eyigor</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physical Medicine and Rehabilitation, Faculty of Medicine, University of Ege, 35100, Bornova, Izmir, Turkey. eyigor@hotmail.com</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Physical Medicine and Rehabilitation, Faculty of Medicine, University of Ege, 35100, Bornova, Izmir</wicri:regionArea>
<wicri:noRegion>Izmir</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Karapolat, Hale" sort="Karapolat, Hale" uniqKey="Karapolat H" first="Hale" last="Karapolat">Hale Karapolat</name>
</author>
<author><name sortKey="Kirazli, Ye Im" sort="Kirazli, Ye Im" uniqKey="Kirazli Y" first="Ye Im" last="Kirazli">Ye Im Kirazli</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18227980</idno>
<idno type="pmid">18227980</idno>
<idno type="doi">10.1007/s12325-008-0006-1</idno>
<idno type="wicri:Area/PubMed/Corpus">003397</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003397</idno>
<idno type="wicri:Area/PubMed/Curation">003397</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003397</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003397</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003397</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of etanercept and complete decongestive physical therapy in bilateral lower-limb lymphoedema associated with rheumatoid arthritis: a case report.</title>
<author><name sortKey="Eyigor, Sibel" sort="Eyigor, Sibel" uniqKey="Eyigor S" first="Sibel" last="Eyigor">Sibel Eyigor</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physical Medicine and Rehabilitation, Faculty of Medicine, University of Ege, 35100, Bornova, Izmir, Turkey. eyigor@hotmail.com</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Physical Medicine and Rehabilitation, Faculty of Medicine, University of Ege, 35100, Bornova, Izmir</wicri:regionArea>
<wicri:noRegion>Izmir</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Karapolat, Hale" sort="Karapolat, Hale" uniqKey="Karapolat H" first="Hale" last="Karapolat">Hale Karapolat</name>
</author>
<author><name sortKey="Kirazli, Ye Im" sort="Kirazli, Ye Im" uniqKey="Kirazli Y" first="Ye Im" last="Kirazli">Ye Im Kirazli</name>
</author>
</analytic>
<series><title level="j">Advances in therapy</title>
<idno type="ISSN">0741-238X</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antirheumatic Agents (therapeutic use)</term>
<term>Arthritis, Rheumatoid (complications)</term>
<term>Combined Modality Therapy</term>
<term>Etanercept</term>
<term>Female</term>
<term>Humans</term>
<term>Immunoglobulin G (therapeutic use)</term>
<term>Lower Extremity</term>
<term>Lymphedema (etiology)</term>
<term>Lymphedema (therapy)</term>
<term>Middle Aged</term>
<term>Physical Therapy Modalities</term>
<term>Receptors, Tumor Necrosis Factor (therapeutic use)</term>
<term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Antirhumatismaux (usage thérapeutique)</term>
<term>Association thérapeutique</term>
<term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunoglobuline G (usage thérapeutique)</term>
<term>Lymphoedème ()</term>
<term>Lymphoedème (étiologie)</term>
<term>Membre inférieur</term>
<term>Polyarthrite rhumatoïde ()</term>
<term>Récepteurs aux facteurs de nécrose tumorale (usage thérapeutique)</term>
<term>Techniques de physiothérapie</term>
<term>Étanercept</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term>
<term>Immunoglobulin G</term>
<term>Receptors, Tumor Necrosis Factor</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Arthritis, Rheumatoid</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirhumatismaux</term>
<term>Immunoglobuline G</term>
<term>Récepteurs aux facteurs de nécrose tumorale</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Combined Modality Therapy</term>
<term>Etanercept</term>
<term>Female</term>
<term>Humans</term>
<term>Lower Extremity</term>
<term>Middle Aged</term>
<term>Physical Therapy Modalities</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Association thérapeutique</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphoedème</term>
<term>Membre inférieur</term>
<term>Polyarthrite rhumatoïde</term>
<term>Techniques de physiothérapie</term>
<term>Étanercept</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A 54-y-old patient with rheumatoid arthritis (RA) and bilateral lower-limb lymphoedema is presented. Complete decongestive physical therapy (CDP) is the cornerstone of the management programme in all patients suffering from lymphoedema associated with RA, but it is not clear which therapy is the most effective in decreasing the oedema. We report on a patient with bilateral lower-limb lymphoedema associated with RA who, after receiving etanercept and CDP, showed moderate improvement. There is little information on the benefit of etanercept therapy for the extra-articular manifestations of RA. Further research is necessary to confirm the beneficial effect of etanercept and CDP.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18227980</PMID>
<DateCreated><Year>2008</Year>
<Month>03</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2009</Year>
<Month>01</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0741-238X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>25</Volume>
<Issue>1</Issue>
<PubDate><Year>2008</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Advances in therapy</Title>
<ISOAbbreviation>Adv Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Efficacy of etanercept and complete decongestive physical therapy in bilateral lower-limb lymphoedema associated with rheumatoid arthritis: a case report.</ArticleTitle>
<Pagination><MedlinePgn>23-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-008-0006-1</ELocationID>
<Abstract><AbstractText>A 54-y-old patient with rheumatoid arthritis (RA) and bilateral lower-limb lymphoedema is presented. Complete decongestive physical therapy (CDP) is the cornerstone of the management programme in all patients suffering from lymphoedema associated with RA, but it is not clear which therapy is the most effective in decreasing the oedema. We report on a patient with bilateral lower-limb lymphoedema associated with RA who, after receiving etanercept and CDP, showed moderate improvement. There is little information on the benefit of etanercept therapy for the extra-articular manifestations of RA. Further research is necessary to confirm the beneficial effect of etanercept and CDP.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eyigor</LastName>
<ForeName>Sibel</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Faculty of Medicine, University of Ege, 35100, Bornova, Izmir, Turkey. eyigor@hotmail.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Karapolat</LastName>
<ForeName>Hale</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kirazli</LastName>
<ForeName>Yeşim</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Adv Ther</MedlineTA>
<NlmUniqueID>8611864</NlmUniqueID>
<ISSNLinking>0741-238X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OP401G7OJC</RegistryNumber>
<NameOfSubstance UI="D000068800">Etanercept</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>T</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068800" MajorTopicYN="N">Etanercept</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D035002" MajorTopicYN="Y">Lower Extremity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D026741" MajorTopicYN="Y">Physical Therapy Modalities</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>1</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>1</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>1</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18227980</ArticleId>
<ArticleId IdType="doi">10.1007/s12325-008-0006-1</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Turquie</li>
</country>
</list>
<tree><noCountry><name sortKey="Karapolat, Hale" sort="Karapolat, Hale" uniqKey="Karapolat H" first="Hale" last="Karapolat">Hale Karapolat</name>
<name sortKey="Kirazli, Ye Im" sort="Kirazli, Ye Im" uniqKey="Kirazli Y" first="Ye Im" last="Kirazli">Ye Im Kirazli</name>
</noCountry>
<country name="Turquie"><noRegion><name sortKey="Eyigor, Sibel" sort="Eyigor, Sibel" uniqKey="Eyigor S" first="Sibel" last="Eyigor">Sibel Eyigor</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003014 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003014 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:18227980 |texte= Efficacy of etanercept and complete decongestive physical therapy in bilateral lower-limb lymphoedema associated with rheumatoid arthritis: a case report. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18227980" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |